Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase …
Full ATHE analysis →
Competitive advantage assessment
Key risks
Revenue Volatility Signals Weak StickinessRevenue volatility is high (stability score 0.21), suggesting weak customer stickiness.
Alterity Therapeutics Limited ranks #303 of 713
scored companies in Biotechnology by moat score — the top 42%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near ATHE in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Not measurable
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 21
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 41
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 89
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Not measurable
· 15% of the moat score
Scale matters only when it converts into economics.
What is Alterity Therapeutics Limited's moat score?
Alterity Therapeutics Limited (ATHE) scores 45 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #303 of 713 scored companies in Biotechnology, the top 42%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (89/100) and its weakest is Customer Stickiness (21/100).
How does Alterity Therapeutics Limited compare with other Biotechnology companies?
Alterity Therapeutics Limited ranks #303 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Alpha Cognition Inc. (ACOG) at 45 just above it and EyePoint Pharmaceuticals, Inc. (EYPT) at 45 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Alterity Therapeutics Limited scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Alterity Therapeutics Limited?
The Corporate Default template measures 6 defenses, and ATHE scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (21), Capital Efficiency (41), Resilience (89), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.